At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 234 enrolled
Drug / intervention
Efprezimod alfa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)·interventional·Posted Mar 20, 2020·Updated Feb 8, 2023
In Brief
A Phase 3 clinical trial evaluating Efprezimod alfa and Placebo for Coronavirus Disease 2019 (COVID-19). Completed, enrolled 234 participants across 10 sites.
Detailed Summary
This study evaluates the efficacy and safety of efprezimod alfa in hospitalized adult participants who are diagnosed with coronavirus disease 2019 (COVID-19) and receiving oxygen support. The primary hypothesis of the study is clinical improvement in the experimental group versus the control group.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCoronavirus Disease 2019 (COVID-19)
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartApr 2020
Primary CompletionOct 2020
TodayJul 2026
First PostedMar 20, 2020
Enrollment StartApr 24, 2020
Primary CompletionOct 20, 2020
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 6.3 years ago
Interventions
Efprezimod alfadrug
Efprezimod alfa is given on Day 1.
Placebodrug
Placebo is given on Day 1.